← All indications
Hyperphosphatemia
A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
Drugs by status
Approved for this indication (2)
Phase 4 trials (9)
Phase 3 trials (7)
Phase 2 trials (7)
Phase 1 trials (5)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (13)
Organization Involved with Phase 3 Indications (33)
- Mitsubishi
- Shire
- Astellas
- Genzyme
- Sanofi
- Novartis
- Ineos Healthcare Limited
- Kissei Pharmaceuticals
- Nabi Biopharmaceuticals
- Vifor Inc.
- Changhai Hospital
- Emory University
- Guangzhou Medical University
- Jilin University
- Qingdao University
- RWTH Aachen University
- Showa University
- Translational Research Informatics Center, Kobe, Hyogo, Japan
- Wuhan University
- Assiut University
- Denver Nephrologists, P.C.
- Dalian Medical University
- Southern Medical University
- Mitsubishi Tanabe
- University of Texas, San Antonio
- Guangdong Pharmaceutical University
- Jiangxi Provincial People's Hospital
- People's Liberation Army of China
- Henan Provincal People's Hospital
- Tonghua Central Hospital
- +3 more
Organization Involved with Phase 2 Indications (18)
- Ilypsa
- Amgen
- Kyowa Hakko Kirin
- KDL Inc.
- Medice Arzneimittel Pütter GmbH & Co KG
- Shield Therapeutics
- CytoPherx
- University of Nottingham
- Vanderbilt University
- LCR Clinical Research
- Denver Nephrology
- Government of China
- Washington University in St. Louis
- Tokai University
- University of Illinois at Chicago
- Jinlin University
- Alebund Pharmaceuticals
- Liaoning Grand Nuokang Biopharmaceutical Co., Ltd.
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (6)